The Comprehensive Cancer Center of Wake Forest University (CCCWFU) is requesting a renewal of its Cancer Center Support Grant from the National Cancer Institute for Years 25 through 29. In the past 3 years, the CCCWFU has experienced consistent growth and achievement: the peer reviewed support base increased from approximately $10 million to over $16 million, substantial new facilities and capital equipment have been added to the Center, the programmatic structure developed three years ago has matured, and all senior leadership positions have been filled. The Cancer Center continues an outstanding record of clinical trials participation and translational research, community-based research in early detection and prevention, and basic science innovation. The CCCWFU has recruited faculty to enhance its cancer focus, has developed novel molecular approaches to cancer diagnosis and therapy, and has a clear or accessible organization with carefully enumerated priorities. Our medical center has maintained its outstanding record of commitment to the Cancer Center. Seven Programs constitute the scientific organization of our Cancer Center: Clinical Trials Program and Breast Program (Clinical Research Division), Early Detection and Medical Outcomes Program and Epidemiology and Prevention Program (Cancer Control Division), and Molecular Diagnosis and Therapy Program, Signaling Program, and DNA Damage and Cellular Defence Program (Basic Science Division).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA012197-25
Application #
2442914
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mccormick, Patricia
Project Start
1976-03-01
Project End
2000-01-31
Budget Start
1998-02-21
Budget End
1999-01-31
Support Year
25
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041418799
City
Winston-Salem
State
NC
Country
United States
Zip Code
27106
Haas, Karen M; Johnson, Kristen L; Phipps, James P et al. (2018) CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens. J Immunol 200:1671-1681
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Suo, Xubin; Eldridge, Brittany N; Zhang, Han et al. (2018) P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes. ACS Appl Mater Interfaces 10:33464-33473
Widner, D Brooke; Park, Sun H; Eber, Matthew R et al. (2018) Interactions Between Disseminated Tumor Cells and Bone Marrow Stromal Cells Regulate Tumor Dormancy. Curr Osteoporos Rep 16:596-602
Liu, Liang; Ruiz, Jimmy; O'Neill, Stacey S et al. (2018) Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 17:81
Sirkisoon, Sherona R; Carpenter, Richard L; Rimkus, Tadas et al. (2018) Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene 37:2502-2514
Goyal, Amrita; Carter, Joi B; Pashtan, Itai et al. (2018) Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study. J Am Acad Dermatol 78:408-410
Su, Weijun; Hong, Lixin; Xu, Xin et al. (2018) miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene 37:5618-5632
Miller Jr, David P; Denizard-Thompson, Nancy; Weaver, Kathryn E et al. (2018) Effect of a Digital Health Intervention on Receipt of Colorectal Cancer Screening in Vulnerable Patients: A Randomized Controlled Trial. Ann Intern Med 168:550-557
Bonin, Keith; Smelser, Amanda; Moreno, Naike Salvador et al. (2018) Structured illumination to spatially map chromatin motions. J Biomed Opt 23:1-8

Showing the most recent 10 out of 548 publications